Marker Therapeutics, Inc.
看多

Marker Therapeutics Receives FDA Orphan Drug Designation for its

172
MRKR: Marker Therapeutics, Inc.
2020-04-29 16:05:00
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。